Skip to main content
    I

    Iovance Biotherapeutics Inc (IOVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.55
    -0.21 (-2.71%)

    Market Cap: $3.59B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Iovance Biotherapeutics Inc (IOVA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Iovance Biotherapeutics reported revenue of $263.50M for the fiscal year ended Dec 31, 2025, up 60.6% from the year before. That year, net income was -$390.98M with a net margin of -148.4%, operating cash flow was -$302.41M and free cash flow was -$336.24M. The quarter ended Sep 30, 2026 had revenue of $121.47M and net income of -$22.27M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$263.50M+60.6%34.3%-153.1%-148.4%
    Dec 2024$164.07M+13699.0%43.2%-240.9%-226.8%
    Dec 2023$1.19MN/A13.1%-38735.0%-37345.4%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$263.50M$164.07M$1.19M$0$0$0$0$0$0$0
    Cost of revenue$173.18M$93.25M$1.03M$0$0$0$0$0$0$0
    Gross profit$90.32M$70.82M$156.00K$0$0$0$0$0$0$0
    Research and development$300.27M$276.23M$333.19M$294.78M$259.04M$201.73M$166.02M$99.83M$71.61M$26.94M
    Operating income-$403.36M-$395.28M-$460.56M-$398.88M-$342.70M-$261.94M-$206.87M-$128.26M-$92.88M-$53.64M
    Net income-$390.98M-$372.18M-$444.04M-$395.89M-$342.25M-$259.58M-$197.56M-$123.58M-$92.06M-$52.89M
    EBITDA-$363.23M-$357.47M-$431.04M-$377.27M-$322.71M-$251.36M-$202.17MN/A-$91.91M-$52.73M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$121.47M$99.31M$71.43M$86.77M$67.45M$59.95M$49.32M$73.69M$58.55M$31.11M$715.00K$482.00K
    Gross profit$73.44M$55.72M$28.93M$58.47M$28.98M$11.07M$6.61M$50.59M$27.04M-$262.00K-$6.55M$5.84M
    Operating income-$23.97M-$51.91M-$81.04M-$73.46M-$94.90M-$113.77M-$121.22M-$86.58M-$89.07M-$101.91M-$117.72M-$121.26M
    Net income-$22.27M-$47.31M-$79.05M-$71.90M-$91.25M-$111.66M-$116.16M-$78.56M-$83.54M-$97.10M-$112.98M-$116.38M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.00M by $162.08M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$913.17M$910.43M$780.35M$663.98M$777.33M$768.46M$344.65M$480.82M$155.37M$171.89M
    Current assets$442.69M$457.02M$307.85M$479.12M$507.96M$636.10M$316.49M$475.37M$149.29M$169.51M
    Cash and equivalents$163.08M$115.69M$114.89M$231.73M$78.23M$67.33M$13.97M$82.15M$145.37M$106.72M
    Total liabilities$214.59M$200.02M$195.74M$164.34M$155.67M$111.96M$45.68M$14.63M$9.89M$4.97M
    Short-term debt$1.00M$0$7.78M$12.59M$5.06M$6.28M$7.25MN/AN/AN/A
    Long-term debtN/A$1.00M$1.00M$1.00M$1.00M$0N/AN/A$0$0
    Shareholder equity$698.58M$710.40M$584.61M$499.64M$621.66M$656.50M$298.97M$466.19M$145.48M$166.92M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$991.21M$915.53M$925.66M$913.17M$904.95M$907.44M$966.74M$910.43M$991.12M$964.32M$869.83M$780.35M
    Total liabilities$178.55M$179.49M$203.91M$214.59M$202.66M$208.95M$198.88M$200.02M$217.66M$195.78M$189.81M$195.74M
    Cash and equivalents$57.93M$110.77M$196.51M$163.08M$158.13M$132.47M$171.67M$115.69M$164.19M$228.68M$134.19M$114.89M
    Shareholder equity$812.66M$736.04M$721.75M$698.58M$702.29M$698.49M$767.87M$710.40M$773.46M$768.54M$680.02M$584.61M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$302.41M-$352.98M-$361.82M-$292.76M-$227.94M-$205.13M-$158.89M-$101.25M-$78.71M-$32.67M
    Capital expenditures$33.84M$11.07M$22.29M$20.43M$37.57M$46.79M$6.92M$1.20M$1.03M$1.52M
    Free cash flow-$336.24M-$364.05M-$384.11M-$313.18M-$265.51M-$251.93M-$165.81M-$102.45M-$79.74M-$34.19M
    Dividends paidN/AN/AN/AN/A$1.00MN/AN/AN/A$0$49.45M
    Investing cash flow$47.50M-$96.41M-$155.24M$256.45M$132.00K-$317.85M$90.03M-$386.28M$58.68M$8.89M
    Financing cash flow$300.77M$390.66M$462.96M$190.15M$239.27M$576.42M$6.13M$424.31M$58.69M$96.90M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.47M-$60.84M-$72.07M-$52.56M-$78.70M-$67.45M-$103.69M-$73.30M-$58.97M-$98.43M-$122.28M-$83.97M
    Capital expenditures$4.74M$5.44M$6.61M$9.32M$10.84M$7.46M$6.21M$4.17M$2.29M$442.00K$4.17M$3.53M
    Free cash flow-$9.21M-$66.28M-$78.68M-$61.88M-$89.55M-$74.91M-$109.91M-$77.46M-$61.26M-$98.87M-$126.45M-$87.50M
    Last 12 quarters

    Frequently Asked Questions About IOVA

    What is Iovance Biotherapeutics' annual revenue?

    Iovance Biotherapeutics reported revenue of $263.50M for the fiscal year ended Dec 31, 2025.

    How fast is Iovance Biotherapeutics' revenue growing?

    Revenue was up 60.6% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Iovance Biotherapeutics profitable?

    No. Iovance Biotherapeutics reported net income of -$390.98M for the fiscal year ended Dec 31, 2025, with a net margin of -148.4%.

    How much free cash flow does IOVA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$302.41M minus capital expenditures of $33.84M produced free cash flow of -$336.24M.

    How much debt does Iovance Biotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.00M and cash and equivalents of $163.08M.